3 completed, 1 active not recruiting. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Recurrent Low Back Pain: new trials by email Literature Review of Recurrent Low Back Pain trials Research Report on Recurrent Low Back Pain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Intradiscal Injection of BM-MSC in Subjects With Chronic Low Back Pain (LBP) Due to Lumbar Degenerative Disc Disease (DDD) Unresponsive Allogenic BM-MSCs Injection, Sham Procedure - Recurrent Low Back Pain, Degenerative Disc Disease (DDD) | Phase 2 / Phase 3 | Active not recruiting | University Hospital, Montpellier | 113 | 2019-02-18 | 2025-09-30 |
| Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies Investigational medical product (IMP) administered in parent study - Osteoarthritis, Cancer Pain | Phase 3 | Completed | Pfizer | 4 | 2017-11-03 | 2021-06-25 |
| Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-042) MK0663, Etoricoxib / Duration of Treatment : 12 Weeks, Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks - Recurrent Low Back Pain | Phase 3 | Completed | Organon and Co | 319 | 2000-04-01 | 2022-02-18 |
| Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041) MK0663, Etoricoxib / Duration of Treatment : 12 Weeks, Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks - Recurrent Low Back Pain | Phase 3 | Completed | Organon and Co | 325 | 2000-04-01 | 2022-02-18 |
Low Back Pain (4) · Cancer Pain (1) · Intervertebral Disc Degeneration (1) · Osteoarthritis (1)
Back Pain (4) · Neurologic Manifestations (4) · Pain (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Musculoskeletal Diseases (2) · Arthritis (1) · Bone Diseases (1) · Joint Diseases (1) · Rheumatic Diseases (1) · Spinal Diseases (1)
Duration of Therapy (2) · Etoricoxib (2) · Inosine Monophosphate (1) · Lidocaine (1)
Organon and Co (2) · Pfizer (1) · University Hospital, Montpellier (1)
France (1) · Germany (1) · Italy (1) · Spain (1) · United States (1)
2017 (1)